Profound Medical Announces Changes to Commercial Organization

Mississauga, Ontario, CANADA

TORONTO, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, announces that Ian Heynen will be resigning from his position as Senior Vice-President of Sale and Marketing to pursue other opportunities, effective January 7, 2019. 

“We would like to thank Ian for his contributions to refining and expanding our commercial capabilities, and wish him well in his future endeavors,” said Arun Menawat, Profound’s CEO. “We expect a seamless transition as Hartmut Warnken, our VP of International Sales, will assume overall commercial management responsibility for those jurisdictions where our technologies are currently cleared for marketing - Europe, where our focus remains on driving clinical adoption of TULSA-PRO® for treating prostate disease and Asia, where we recently initiated the launch of Sonalleve® for the treatment of uterine fibroids. Moving forward, our commercial team will also continue to prepare for the anticipated U.S. launch of TULSA-PRO® in 2019.”

About Profound Medical Corp.

Profound is developing and commercializing therapeutic platforms that combine the power of real-time magnetic resonance (MR) imaging and non-invasive ultrasound ablation. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patients and clinicians in many anatomies and disease states, including prostate disease (localized prostate cancer and benign prostatic hyperplasia), uterine fibroids, and bone metastases. Profound mission is to “profoundly” change the standard of care whereby clinicians can confidently ablate tissue with precision, and patients can access safe and effective treatment options and quickly return to their daily lives.

Profound’s novel TULSA-PRO® system combines real-time MR imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. TULSA-PRO® is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE marked and is undergoing a pilot commercial launch in key European and other CE mark jurisdictions. Profound is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which if successful, is expected to support its application to the FDA for clearance to market TULSA-PRO® in the United States.

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to enable precise and incision-free ablation of diseased tissue. Sonalleve® is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The technology was also recently approved by the Chinese Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve®, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy, where the technology has been shown to have clinical application.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
T: 647.872.4849